γ-AApeptides as a New Strategy for Therapeutic Development

Author(s): Alekhya Nimmagadda, Yan Shi, Jianfeng Cai*.

Journal Name: Current Medicinal Chemistry

Volume 26 , Issue 13 , 2019

Become EABM
Become Reviewer

Abstract:

A new class of peptidomimetics termed as "γ-AApeptides" was recently developed by our group. Similar to other peptidomimetics, γ-AApeptides are resistant to proteolytic degradation, and possess limitless potential to introduce chemically diverse functional groups. γ-AApeptides have shown great promise in biomedical applications. In this article, we will review a few examples of γ-AApeptides with biological potential. Certain γ-AApeptides can permeate cell membranes and therefore they can be used as potential drug carrier. γ-AApeptides can also bind to HIV RNA with high specificity and affinity, suggesting their potential application as anti-HIV agents. Moreover, they can mimic host-defense peptides and display potent and broad-spectrum activity towards a range of drug-resistant bacterial pathogens. They are also potential anti-cancer agents. For instance, they have shown great promise in targeted imaging of tumor in mouse model, and they are also capable of disrupting p53/DNA interactions, and thus antagonize STAT3 signaling pathway. Recently, from combinatorial screening, γ-AApeptides are identified to inhibit Aβ peptide aggregation, and thus they can be developed into potential anti- Alzheimer’s disease agent.

Keywords: γ-AApeptides, peptidomimetics, structures, anticancer activity, antimicrobial activity, anti-HIV activity, anti-Aβ aggregation.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 26
ISSUE: 13
Year: 2019
Page: [2313 - 2329]
Pages: 17
DOI: 10.2174/0929867324666171107095913
Price: $58

Article Metrics

PDF: 15